GP30101 + Prezista® + GP30101 + Prezista®

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioequivalence

Conditions

Bioequivalence

Trial Timeline

Jun 6, 2019 → Sep 6, 2019

About GP30101 + Prezista® + GP30101 + Prezista®

GP30101 + Prezista® + GP30101 + Prezista® is a pre-clinical stage product being developed by GEROPHARM for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT04268472. Target conditions include Bioequivalence.

Hype Score Breakdown

Clinical
5
Activity
2
Company
2
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT04268472Pre-clinicalCompleted

Competing Products

20 competing products in Bioequivalence

See all competitors
ProductCompanyStageHype Score
Bupropion HCl MR tablets 300mgAlembic PharmaceuticalsPhase 1
32
Fingolimod 0.5 mg capsules- Test drugAlembic PharmaceuticalsPhase 1
32
Lamotrigine ER tablet 50mgAlembic PharmaceuticalsPhase 1
32
Sonelokimab + SonelokimabMoonLake ImmunotherapeuticsPhase 1
28
Metformin + Glucophage® + Metformin + Glucophage®GEROPHARMPhase 1
25
Metformine + Glucophage® Long + Metformin + Glucophage® LongGEROPHARMPhase 1
25
Humulin® Regular + Rinsulin® RGEROPHARMPre-clinical
15
Bosentan 125 mg + Tracleer 125Mg TabletGEROPHARMPhase 1
25
Rinsulin® mix 30/70 + Humulin® M3GEROPHARMPre-clinical
15
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
25
Clocortolone PivalateSun PharmaceuticalPhase 1
33
Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + PlaceboSun PharmaceuticalPhase 1
33
Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solutionJohnson & JohnsonPhase 1
33
SHR-1314Jiangsu Hengrui MedicinePhase 1
33
Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metforminAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
OmeprazoleAstraZenecaPhase 1
33
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)AstraZenecaPhase 1
33
D961S + Esomeprazole + Buffered acetylsalicylic acidAstraZenecaPhase 1
33
Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsuleAstraZenecaPhase 1
33